167 related articles for article (PubMed ID: 31480886)
1. A Retrospective Review of Angiotensin II Use in Adult Patients With Refractory Distributive Shock.
Wong A; Alkazemi A; Eche IM; Petri CR; Sarge T; Cocchi MN
J Intensive Care Med; 2020 Dec; 35(12):1490-1496. PubMed ID: 31480886
[TBL] [Abstract][Full Text] [Related]
2. Intravenous angiotensin II for the treatment of high-output shock (ATHOS trial): a pilot study.
Chawla LS; Busse L; Brasha-Mitchell E; Davison D; Honiq J; Alotaibi Z; Seneff MG
Crit Care; 2014 Oct; 18(5):534. PubMed ID: 25286986
[TBL] [Abstract][Full Text] [Related]
3. Angiotensin II: A New Vasopressor for the Treatment of Distributive Shock.
Allen JM; Gilbert BW
Clin Ther; 2019 Dec; 41(12):2594-2610. PubMed ID: 31668356
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of Angiotensin II for Catecholamine Refractory Septic or Distributive Shock on Mortality: A Propensity Score Weighted Analysis of Real-World Experience in the Medical ICU.
Quan M; Cho N; Bushell T; Mak J; Nguyen N; Litwak J; Rockwood N; Nguyen HB
Crit Care Explor; 2022 Jan; 4(1):e0623. PubMed ID: 35072084
[TBL] [Abstract][Full Text] [Related]
5. Effects of angiotensin II in the management of perioperative hypotension in kidney transplant recipients.
Andrews L; Benken J; Benedetti E; Nishioka H; Pierce D; Dalton K; Han J; Shin B; Benken S
Clin Transplant; 2022 Sep; 36(9):e14754. PubMed ID: 35771088
[TBL] [Abstract][Full Text] [Related]
6. Angiotensin II in the treatment of distributive shock: a systematic-review and meta-analysis.
Xourgia E; Exadaktylos AK; Chalkias A; Ziaka M
Shock; 2024 Jun; ():. PubMed ID: 38888542
[TBL] [Abstract][Full Text] [Related]
7. Angiotensin II and Vasopressin for Vasodilatory Shock: A Critical Appraisal of Catecholamine-Sparing Strategies.
Heavner MS; McCurdy MT; Mazzeffi MA; Galvagno SM; Tanaka KA; Chow JH
J Intensive Care Med; 2021 Jun; 36(6):635-645. PubMed ID: 32223515
[TBL] [Abstract][Full Text] [Related]
8. Angiotensin II for the treatment of distributive shock in the intensive care unit: A US cost-effectiveness analysis.
Busse LW; Nicholson G; Nordyke RJ; Lee CH; Zeng F; Albertson TE
Int J Technol Assess Health Care; 2020 Apr; 36(2):145-151. PubMed ID: 32114996
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Vasopressin as First-Line Treatment of Distributive and Hemorrhagic Shock States.
Haan BJ; Cadiz ML; Natavio AM
Ann Pharmacother; 2020 Mar; 54(3):213-218. PubMed ID: 31625395
[No Abstract] [Full Text] [Related]
10. Association of Vasopressin Plus Catecholamine Vasopressors vs Catecholamines Alone With Atrial Fibrillation in Patients With Distributive Shock: A Systematic Review and Meta-analysis.
McIntyre WF; Um KJ; Alhazzani W; Lengyel AP; Hajjar L; Gordon AC; Lamontagne F; Healey JS; Whitlock RP; Belley-Côté EP
JAMA; 2018 May; 319(18):1889-1900. PubMed ID: 29801010
[TBL] [Abstract][Full Text] [Related]
11. FDA Approval of Angiotensin II for the Treatment of Hypotension in Adults with Distributive Shock.
Senatore F; Jagadeesh G; Rose M; Pillai VC; Hariharan S; Liu Q; McDowell TY; Sapru MK; Southworth MR; Stockbridge N
Am J Cardiovasc Drugs; 2019 Feb; 19(1):11-20. PubMed ID: 30144016
[TBL] [Abstract][Full Text] [Related]
12. Angiotensin II in septic shock.
Jadhav AP; Sadaka FG
Am J Emerg Med; 2019 Jun; 37(6):1169-1174. PubMed ID: 30935784
[TBL] [Abstract][Full Text] [Related]
13. The Role of Angiotensin II in Poisoning-Induced Shock-a Review.
Chen A; Wong A
J Med Toxicol; 2022 Apr; 18(2):145-154. PubMed ID: 35258848
[TBL] [Abstract][Full Text] [Related]
14. Novel Vasopressors in the Treatment of Vasodilatory Shock: A Systematic Review of Angiotensin II, Selepressin, and Terlipressin.
Rodriguez R; Cucci M; Kane S; Fernandez E; Benken S
J Intensive Care Med; 2020 Apr; 35(4):327-337. PubMed ID: 30563433
[TBL] [Abstract][Full Text] [Related]
15. Angiotensin II (Giapreza): A Distinct Mechanism for the Treatment of Vasodilatory Shock.
Khalique SC; Ferguson N
Cardiol Rev; 2019; 27(3):167-169. PubMed ID: 30601161
[TBL] [Abstract][Full Text] [Related]
16. Angiotensin II: a new approach for refractory shock management?
Kimmoun A; Levy B
Crit Care; 2014 Dec; 18(6):694. PubMed ID: 25645552
[TBL] [Abstract][Full Text] [Related]
17. A Multicenter Observational Cohort Study of Angiotensin II in Shock.
Smith SE; Newsome AS; Guo Y; Hecht J; McCurdy MT; Mazzeffi MA; Chow JH; Kethireddy S
J Intensive Care Med; 2022 Jan; 37(1):75-82. PubMed ID: 33231111
[TBL] [Abstract][Full Text] [Related]
18. Role of angiotensin II in treatment of refractory distributive shock.
Rodriguez R; Fernandez EM
Am J Health Syst Pharm; 2019 Jan; 76(2):101-107. PubMed ID: 31361800
[TBL] [Abstract][Full Text] [Related]
19. Angiotensin II Infusion for Shock: A Multicenter Study of Postmarketing Use.
Wieruszewski PM; Wittwer ED; Kashani KB; Brown DR; Butler SO; Clark AM; Cooper CJ; Davison DL; Gajic O; Gunnerson KJ; Tendler R; Mara KC; Barreto EF
Chest; 2021 Feb; 159(2):596-605. PubMed ID: 32882250
[TBL] [Abstract][Full Text] [Related]
20. Broad spectrum vasopressors: a new approach to the initial management of septic shock?
Chawla LS; Ostermann M; Forni L; Tidmarsh GF
Crit Care; 2019 Apr; 23(1):124. PubMed ID: 30992045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
